Travere Therapeutics, Inc. (TVTX)

Market Cap	2.91B +106.2%
Revenue (ttm)	435.83M +114.2%
Net Income	-88.54M
EPS	-1.02
Shares Out	89.47M
PE Ratio	n/a
Forward PE	25.85
Dividend	n/a
Ex-Dividend Date	n/a

Volume	526,225
Open	31.09
Previous Close	31.09
Day's Range	31.04 - 32.80
52-Week Range	12.91 - 42.13
Beta	0.85
Analysts	Strong Buy
Price Target	37.21 (+14.49%)
Earnings Date	Feb 19, 2026

About TVTX

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company’s products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 385
• Stock Exchange: NASDAQ
• Ticker Symbol: TVTX
• Website: https://www.travere.com

Financial Performance

In 2024, Travere Therapeutics's revenue was $233.18 million, an increase of 60.55% compared to the previous year's $145.24 million. Losses were -$321.55 million, 188.6% more than in 2023.

Analyst Summary

According to 15 analysts, the average rating for TVTX stock is "Strong Buy." The 12-month stock price target is $37.21, which is an increase of 14.49% from the latest price.

Price Target

$37.21

(14.49% upside)

Analyst Consensus: Strong Buy